Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446944 | 0.67 | ALOX15 (0.39) | MAOAMAOBCA1CA2NPC1 | |
| SCHEMBL1623564 | 0.66 | — | — | |
| SCHEMBL59871 | 0.66 | — | — | |
| SCHEMBL1162905 | 0.66 | TSHR (0.42) | MAOAMAOBTSHR | |
| SCHEMBL29471383 | 0.66 | — | — | |
| SCHEMBL4486486 | 0.66 | TSHR (0.42) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL30473446 | 0.66 | TSHR (0.42) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL157430 | 0.66 | — | — | |
| SCHEMBL20477699 | 0.66 | TSHR (0.42) | MAOAMAOBTSHR | |
| SCHEMBL2851479 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | claimed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | claimed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | claimed |
| EP-2134342-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | claimed |
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3559007-A1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3319970-B1 | PYRIDO-OXAZINONE DERIVATIVES AS TNAP INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
| EP-2134342-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009126635-A1 | 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | MAOA 2128/4885MAOB 2268/4885TSHR 2551/4885 |
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ROCK1, ROCK2, RHOA | MAOA 1512/4885MAOB 1399/4885TSHR 1979/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | MAOA 1308/4885MAOB 1126/4885TSHR 3357/4885 |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | MAOA 935/4885MAOB 536/4885TSHR 725/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | MAOA 2128/4885MAOB 2268/4885TSHR 2551/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | MAOA 487/4885MAOB 320/4885TSHR 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.